Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

LATEST NEWS

Terumo Blood and Cell Technologies Joins Cell Manufacturing Research Initiative to Help Advance Cell Therapy Discoveries

Swiss Approve Mirasol Pathogen Reduction Technology System to Treat Platelets

Terumo Blood and Cell Technologies Announces Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020 for Asia Pacific

Terumo Blood and Cell Technologies Accepting Advancing Apheresis Award 2020 Applications

First Lady of Ghana Encourages Healthy Ghanaians to Become Champions of Change and Donate Blood to Save Lives

Terumo BCT Evolves Brand to Terumo Blood and Cell Technologies

Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults

A Look Inside Terumo BCT's Impact on Convalescent Plasma for COVID-19

First COVID-19 Patient Receives Therapy Targeting Cytokine Storm Under FDA EUA

Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}